I have a flow system

Chapter 190 The Future of Aiying Biology

Regarding the matter of stocks, because of the help of the system, after I have a solid mind, the communication with the investment advisor will become more rigid.

No matter how much he persuaded, Wu Zhou remained still.

Insist on selling plus insist on shorting.

In the end, the consultant had no choice but to compromise and continue to follow what Wu Zhou said.

The next day, not surprisingly, the ZF department issued a lot of good news to boost confidence in the stock market.

Many stocks even rose red because of this, but Tesla was not among them.

At the same time, short-selling ETFs are also buying one after another, and this is the best time to buy.

In Wu Zhou in Huaxia, Wu Zhou would glance at these transactions in the morning the next day.

But after turning around, I had to get busy again.

Medical device companies are still consolidating.

But Aiying Biopharmaceutical Co., Ltd. has been sorted out in sevens and eighties.

Talents are also arriving one after another.

In the eyes of the management and employees of Aiying Biotechnology, seeing the entry of big names one by one, these old employees who are at ease in research and development are getting more and more confident.

And after these big cows joined the company, they also discovered that what they had promised before would arrive immediately.

Just like the 1 million R&D funds, they will be credited immediately upon arrival.

Then there is the company's work content, and there is no need to care about the social issues of those Lao Shizi, they just need to stay in the laboratory with peace of mind and do their favorite experiments.

As for the ordinary researchers below, although many of these big cows may not know each other, after working for a while, they can feel the strength of each other.

Leaders with such strong research and development capabilities have joined the company one after another, so why not worry about future development.

All of these have gradually enriched their confidence.

He even began to look forward to the future, whether Aiying Biotech will become one of the world's leading pharmaceutical companies in the future.

Biomedicine is very difficult to do.

Many netizens' comments on Wu Zhou, although emotional, may also be a little harsh, but they are not completely wrong.

If Wu Zhou is a person without a system, or if Wu Zhou didn't work out the targeted push function of the system.

In the medical field, there is a high probability that Wu Zhou would not dare to set foot in it.

For example, the top pharmaceutical foreign company, Roche Pharmaceuticals, has such a description map.

1000000000 Swiss francs (about the same value as the US dollar) capital investment
7000874 hours of work (equivalent to one person, 799 years of endless work)
6587 scientific studies
423 researchers

1 drug

This is the normal model of the drug development process of Roche Pharmaceuticals, a top pharmaceutical company.

Generally, the early research of a drug is to screen compounds, and about 5000-10000 compounds are screened to select an auspicious number, such as 1, for preclinical research.

This process generally takes 3-6 years.

这250个化合物大概能有5个能进入到临床研究，就是那什么1期，2期和3期临床，这个过程大概是6-7年。

The last thing is to approve the listing. It is estimated that one can be approved, which is a 1% success rate. This process will take about 20 to 0.5 years.

In total, the shortest time is 3+6+0.5=9.5 years.

Judging from these times.

The first item is compound screening. Less than 5% of nearly [-] compounds can enter the next round.

In other words, 95% of the working time is wasted.

If the system participates in the screening, it will increase sales by 20 times, and even in one step, directly select the last drug that can be marketed.

That is an efficiency improvement of tens of thousands of times.

Although the research and development costs cannot be saved tens of thousands of times.

But saving ten times and a hundred times is not a big problem.

The conclusion is that other people have tens of billions, and Wu Zhou has about 1-10 million, and he can almost make one.

Of course, the above only exists in theory, and it must not be done in practice.

After all, the success rate is unreasonably high, and it is easy to be noticed.

Of course, Wu Zhou also thought of some compromises.

And it is already being implemented.

First of all, from the perspective of compound screening, some geniuses are born with good luck. It just so happened that Wu Zhou's company recruited him, and it just so happened that he came to the company's R&D department, and then...
Of course, pure luck doesn't last long. In the early stage, Wu Zhou can try his best to speed up the company's development, but in the later stage, the company must recycle itself.

Only in this way can it last for a long time, and can there be a steady stream of good things coming out.

Of course, the most important thing is that only in this way can Wu Zhou's time be freed up.

Biochemical materials is a tiankeng industry jokingly called by many netizens and students. The main reason is that employment is relatively poor and wages are much lower than popular industries.

However, wages can only represent a moment, not a lifetime. The importance of these industries is self-evident.

It's just that the market demand is not so much. In addition, we have a large population, and the salary will drop accordingly.

So, after Wu Zhou contacted these colleges and universities.

The recruitment process was fairly smooth, and the recent advance approval is already in progress.

Institutions above 211, the starting salary is 1+ for undergraduates, 1.5-2w+ for masters, and 3+ for doctors.

The salary package given is about double the current industry price.

Of course, this is for ordinary talents and special talents, so this salary is definitely not acceptable.

The company has a special genius plan here, which imitates Huawei's "genius plan".

Provide a sufficient and free research and development environment, research and development funds, plus high salaries in the industry.

Talents are different, and the salary is of course different, purely from the perspective of salary.

It is mainly divided into three grades.

The third gear is, 70-100

The second gear is 130-150 million

The first gear is 180-200 million

A breakthrough in a field often depends on one or two geniuses.

What's more, the "Hundred Talents Project" of Aiying Biology, a company of Wu Zhou, is still going on. Almost all of them are top-level scientific research talents. Some people have not made real achievements, but the time has not yet come , or the research is in the wrong direction, and time is wasted.

After all, success depends not only on strength, but also on luck.

Wu Zhou will give them plenty of opportunities and direction, and even find them a suitable partner, so that they can achieve more brilliant results.

With the help of the system, the future is still very promising.

Thirdly, it is the artificial intelligence system.

This is one of the cutting-edge technologies at the moment.

The artificial intelligence system has very strong innate advantages, which can greatly help human beings improve the productivity of research and development, and greatly improve the efficiency and progress of research and development.

And as long as there is sufficient data, artificial intelligence can continue to grow through self-learning.

It is almost impossible to retrieve those big data with the human brain, but for artificial intelligence, these are the basic operations.

In this regard, China still has an advantage. At present, in the field of artificial intelligence in the world, there are actually only two players, one from the United States and one from us.

There are actually top experts, top companies, and top products in the field of artificial intelligence in China.

Of course, these involve spending money.

Fortunately, Wu Zhou has a lot of money
Of course, these are still opportunistic 'step by step'.

No matter how to improve efficiency, some processes need so much time.

Therefore, if new drugs are created from scratch, then Wu Zhou's Aiying Biotechnology will probably start to have breakthrough results after ten years.
Still too long.

Still have to think of new ways.

For example, buy buy buy.
(End of this chapter)